Are neurofilaments valuable biomarkers for long-term disease prognostication in MS?

Abstract

Get full access to this article

View all access options for this article.

References

Teunissen

Khalil

Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18(5): 552–556.

Khalil

Teunissen

Otto

et al.

Neurofilaments as promising biomarkers in neurological disorders. Nat Rev Neurol, 2018, accepted article.

Petzold

The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up. J Neurol Neurosurg Psychiatry 2015; 86(12): 1388–1390.

Khalil

Salzer

CSF neurofilament light: A universal risk biomarker in multiple sclerosis?

Neurology 2016; 87(11): 1068–1069.

Rissin

Kan

Campbell

et al . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010; 28(6): 595–599.

Disanto

Barro

Benkert

et al . Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81(6): 857–870.

Barro

Benkert

Disanto

et al . Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. Epub ahead of print 30 may 2018. DOI: 10.1093/brain/awy154.

Kuhle

Barro

Disanto

et al . Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler 2016; 22: 1550–1559.

Piehl

Kockum

Khademi

et al . Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler 2017; 24: 1046–1054.

10.

Salzer

Svenningsson

Sundström

Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16(3): 287–292.

11.

Bhan

Jacobsen

Myhr

et al.

Neurofilaments and 10-year follow up in multiple sclerosis. Mult Scler, 2018; 24: 1301–1307.